[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354063-105":59,"doc-detail-354063-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","efficacy-and-immunogenic-effects-of-tumor-treating-fields-ttfields-in-preclinical-models-of-pancreatic-ductal-adenocarcinoma","Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma","","Tumor Treating Fields (TTFields) is an approved modality for glioblastoma, pleural mesothelioma, and non-small cell lung cancer. This preclinical study tests TTFields in pancreatic ductal adenocarcinoma models, where KRAS-driven disease is linked to aggressive behavior and therapy resistance. TTFields markedly suppresses c-Myc and triggers immunogenic cell death via increased calreticulin surface exposure, extracellular ATP release, and HMGB1 secretion, further strengthened by gemcitabine/nab-paclitaxel. TTFields also induces systemic immune activation with dendritic cell activation, expanded effector memory T cells, and enhanced tumor immune infiltration.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/efficacy-and-immunogenic-effects-of-tumor-treating-fields-ttfields-in-preclinical-models-of-pancreatic-ductal-adenocarcinoma/354063/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/efficacy-and-immunogenic-effects-of-tumor-treating-fields-ttfields-in-preclinical-models-of-pancreatic-ductal-adenocarcinoma/354063.png","ImageObject",300,407,{"name":92,"@type":93},"Sarah ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does TTFields affect c-Myc and immunogenic cell death in pancreatic cancer models?","Question",{"text":112,"@type":113},"TTFields application significantly suppresses c-Myc expression and induces immunogenic cell death, marked by increased calreticulin cell-surface exposure, extracellular ATP secretion, and elevated HMGB1 release. These effects are further enhanced when TTFields are combined with gemcitabine/nab-paclitaxel.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What immune effects are observed after TTFields treatment in vivo?",{"text":117,"@type":113},"In vivo, TTFields induces a systemic immune response, including dendritic cell activation, increased effector memory T cells, and greater tumor leukocyte infiltration. The study reports these immune readouts but does not establish direct causality between c-Myc modulation and immune changes.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the significance of combining TTFields with gemcitabine/nab-paclitaxel for pancreatic ductal adenocarcinoma?",{"text":121,"@type":113},"Concomitant TTFields with gemcitabine/nab-paclitaxel reduces tumor volume, decreases monocytic myeloid-derived suppressor cells (M-MDSC), and increases the tumor lymphocyte-to-monocyte ratio compared with other groups. These results support exploring TTFields to enhance therapeutic efficacy and enable combination with immunotherapies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354063,1790154788,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962085320529,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","DOI: 10.1002/ijc.70408  \nSHORT REPORT  \nCancer Therapy a nd Prevention  \nEfficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductaladenocarcinoma, with and without gemcitabine/nab-paclitaxel  \nTal Kan 1 | Tharwat Haj Khalil 1 | Yiftah Barsheshet 1 | Tali Voloshin 1 | Lilach Koren 1 | Bella Koltun 1 | Cfir David 1 | Kerem Wainer-Katsir 1 | Avital Vorontsova 1 | Boris Brant 1 | Simona Zisman-Rozen 1 | Hila M. Ene 1 | Roni Frechtel-Gerzi 1 | Shay Cahal 1 | Anat Klein-Goldberg 1 | Lena Lifshitz 1 | Efrat Zemer Tov 1 | Mai Shai 1 | Adi Haber 1 | Moshe Giladi 1  | Uri Weinberg 2 | Yoram Palti 1  \n1Novocure Ltd., Haifa, Israel  \n2Novocure GmbH, Baar, Switzerland  \nCorrespondence  \nMoshe Giladi and Tali Voloshin, Novocure Ltd., Haifa, Israel.  \n[Email:](Email: mosheg@novocure.com)[ mosheg@novocure.com](Email: mosheg@novocure.com); tvoloshinsela@ [novocure.com](novocure.com)  \nFunding information Novocure  \nAbstract  \nTumor Treating Fields (TTFields) are an approved cancer therapy for glioblastoma (GBM), pleural mesothelioma, and non-small cell lung cancer (NSCLC) . A recent phase 3 trial of TTFields therapy concomitant with standard-of-care gemcitabine and nabpaclitaxel (Gem/NabP) as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma demonstrated a significant increase in overall survival. The current study evaluated the effects of TTFields in preclinical pancreatic ductaladenocarcinoma (PDAC) models. The vast majority of PDAC patients harbor KRAS mutations, which are associated with a more aggressive disease phenotype and increased therapy resistance, driven in part by overexpression of the key transcription factor c-Myc. In the current study, TTFields application significantly suppressed c-Myc expression and induced immunogenic cell death (ICD)—characterized by increased calreticulin cell-surface exposure, extracellular ATP secretion, and elevated HMGB1 release—in pancreatic cancer models. These effects were further enhanced when TTFields were applied concomitantly with Gem/NabP. Causality between c-Myc modulation and immune readouts was not established. In vivo, TTFields application induced a systemic immune response, evidenced by dendritic cell activation, increased effector memory T cells, and greater tumor leukocyte infiltration. TTFields  \nAbbreviations: 7-AAD, 7-aminoactinomycin D; AnnV, annexin V; APCs, antigen-presenting cells; ATCC, American Type Culture Collection; BLI, bioluminescence imaging; cDNA, complementary DNA; CRT, calreticulin; DCs, dendritic cells; eIF2α, eukaryotic translation initiation factor 2α; FDR, false discovery rate; FOLFIRINOX, fluorouracil, irinotecan and oxaliplatin; GBM, glioblastoma; GSEA, gene set enrichment analysis; HMGB1, high-mobility group box 1; HRP, horseradish peroxidase; IC50, half maximal inhibitory concentration; ICD, immunogenic cell death; ICIs, immune checkpoint inhibitors; LMR, lymphocyte to monocyte ratio; MHC-II, major histocompatibility complex class II; M-MDSCs, monocytic myeloid-derived suppressor cells; NabP, nab-paclitaxel; NES, normalized enrichment score; NSCLC, non-small cell lung cancer; PBMCs, peripheral blood mononuclear cells; PCA, principal component analysis; PDAC, pancreatic ductal adenocarcinoma; QA, quinacrine dihydrochloride; qPCR, quantitative polymerase chain reaction; SD, standard deviation; SEM, standard error of the mean; STR, short tandem repeat; TME, tumor microenvironment; TTFields, Tumor Treating Fields.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s) . International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.  \nconcomitant with Gem/NabP significantly reduced tumor volume, decreased tumor monocytic myeloid-derived suppressor cells (M-MDSC), and increased the tumor ly","cbCaibOTQ83fQRcZ","https://ap.wps.com/l/cbCaibOTQ83fQRcZ","pdf",4223815,"English","# Abstract\n# Introduction\n## Epidemiology and clinical burden of pancreatic cancer\n## PDAC prevalence and survival outcomes\n# Methods and abbreviations\n# Key findings and translational implications","[{\"question\":\"How does TTFields affect c-Myc and immunogenic cell death in pancreatic cancer models?\",\"answer\":\"TTFields application significantly suppresses c-Myc expression and induces immunogenic cell death, marked by increased calreticulin cell-surface exposure, extracellular ATP secretion, and elevated HMGB1 release. These effects are further enhanced when TTFields are combined with gemcitabine/nab-paclitaxel.\"},{\"question\":\"What immune effects are observed after TTFields treatment in vivo?\",\"answer\":\"In vivo, TTFields induces a systemic immune response, including dendritic cell activation, increased effector memory T cells, and greater tumor leukocyte infiltration. The study reports these immune readouts but does not establish direct causality between c-Myc modulation and immune changes.\"},{\"question\":\"What is the significance of combining TTFields with gemcitabine/nab-paclitaxel for pancreatic ductal adenocarcinoma?\",\"answer\":\"Concomitant TTFields with gemcitabine/nab-paclitaxel reduces tumor volume, decreases monocytic myeloid-derived suppressor cells (M-MDSC), and increases the tumor lymphocyte-to-monocyte ratio compared with other groups. These results support exploring TTFields to enhance therapeutic efficacy and enable combination with immunotherapies.\"}]","Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma | PDF",1790108664,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/09b61474aa328384a22262a42468acae.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/567ae57b9225b2360cd89593cd7fdb31.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/735c15b895dff64200402e42f77b401c.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9be7aae6d34870ed8bb840a928a4e07b.webp",980,1287]